Immunotherapy for Renal Cell Cancer (RCC)
Agent n Phase References Proleukin (IL-2) 255 Phase II Fyfe G. et al. [19] IFN-α 350 Meta-analysis Medical Research (vs medroxyprogesterone acetate) Council Renal Cancer Collaborators [22] IFN-α+ VLB 160…
ONCOLOGY
Molecular Genetics of Renal Cell Carcinoma
Fig. 3.1 Molecular characterization of clear-cell renal cell carcinoma PBRM1 3.2.2 Mutations of Chromatin Enzymes The importance of chromatin dynamics and its dysregulation in tumorigenesis is increasingly appreciated since the…
Epidemiology of Renal Cell Carcinoma
Continents Incidence Mortality North America Male 15.5 3.7 Female 8.3 1.6 Both 11.7 2.6 Europe Male 12.3 4.8 Female 5.9 1.9 Both 8.8 3.1 Oceania Male 11.0 2.8 Female 5.3…
Forthcoming Drugs for Metastatic Renal Cell Carcinoma Therapy
Agent Molecular targets Phase (comparator) Patient population Clinical activity in RCC References Tivozanib (AV-951) VEGFR-1, 2, 3 Phase III (TIVO-1) (vs. sorafenib) Clear cell RCC PFS (11.9 vs. 9.1 mo)…
Refractory Mechanisms
© Springer Japan KK 2017Mototsugu Oya (ed.)Renal Cell Carcinoma10.1007/978-4-431-55531-5_15 15. Refractory Mechanisms Mototsugu Oya1 , Toshiaki Shinojima1 and Ryuichi Mizuno1 (1) Department of Urology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan Mototsugu Oya Email:…
Treatment for Non-clear Cell Renal Cell Carcinoma
Author Study design Setting Population Treatment line Patients, n Patients with NCCRCC, n NCCRCC histologies Targeted agent Ratain et al. [5] 2 Metastatic RCC 2nd 152 15 PRCC Sorafenib Stadler…
Mammalian Targets of Rapamycin Inhibitors: Temsirolimus and Everolimus
Characteristic Temsirolimus Everolimus Study population Treatment-naive patients with poor-risk disease Patients who had progressed on prior sunitinib and/or sorafenib Number of patients 626 410 Randomization Temsirolimus vs. temsirolimus/IFN-α vs. IFN-α…
Tyrosine Kinase Inhibitors: Sorafenib, Sunitinib, Axitinib, and Pazopanib
Treatment Number of patients Line of treatment ORR (%) PFS (months) OS (months) Sorafenib vs. placebo [13, 14] 903 Second line 10 vs. 2 5.5 vs. 2.8 (p < 0.01) 17.8 vs….
Predictive and Prognostic Markers in Metastatic Renal Cell Carcinoma
Similar trial and Inclusion criteria Agents Number of patients Months (95 % IC) Number of patients Months (95 % IC) Patients receiving first-line TT mOS from patients in IMDC PFS from patients…
Surgical Treatment for Renal Cell Carcinoma
System Variables 1 pt 2 pts 3 pts RENAL Radius (maximal diameter) R ≤ 4 cm 4 < R ≤ 7 cm R ≥ 7 cm Low complexity: 4–6 Exo-/endophytic ≥50 % <50 % Endophytic Moderate complexity: 7–9 Nearness to collecting system/sinus N ≥ 7 mm 4 < N < 7 mm ≤4 mm High…
